Skip to main content
SpringerLink
Log in

Substance Use Disorders in Women

  • Chapter
  • First Online:
Neurology and Psychiatry of Women

  • 866 Accesses

Abstract

Substance use disorders (SUD) in reproductive-aged women represent a significant public health concern. Although SUD are more common in men than women, reports of rising rates of SUD in young women suggest the gender gap may be narrowing. Moreover, women develop more severe SUD more quickly than men and are more likely to suffer from disorders that are complicated by a number of psychiatric comorbidities, including depressive disorders, anxiety disorders, eating disorders, and trauma-related disorders. This chapter will review how sex and gender influence the clinical manifestations, course and treatment of SUD in women, with a special emphasis on pregnancy. Following a general overview, gender-based issues related to specific substances will be discussed, including tobacco, alcohol, opioids, marijuana, cocaine and methamphetamine, highlighting that SUD in women warrant special attention and the need for future research.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 79.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

Introduction References

  1. Center for Behavioral Health Statistics and Quality. 2016 national survey on drug use and health: detailed tables. Rockville: Substance Abuse and Mental Health Services Administration; 2017.

    Google Scholar 

  2. Hasin DS, O’Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, Compton WM, Crowley T, Ling W, Petry NM, Schuckit M. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatr. 2013;170(8):834–51.

    Article  PubMed  Google Scholar 

  3. Hernandez-Avila CA, Rounsaville BJ, Kranzler HR. Opioid-, cannabis-and alcohol-dependent women show more rapid progression to substance abuse treatment. Drug Alcohol Depend. 2004;74(3):265–72.

    Article  CAS  PubMed  Google Scholar 

  4. Grella CE, Scott CK, Foss MA, Joshi V, Hser YI. Gender differences in drug treatment outcomes among participants in the Chicago target cities study. Eval Program Plann. 2003;26(3):297–310.

    Article  Google Scholar 

  5. Greenfield SF, Back SE, Lawson K, Brady KT. Substance abuse in women. Psychiatr Clin. 2010;33(2):339–55.

    Google Scholar 

  6. Substance Abuse and Mental Health Services Administration. Substance abuse treatment: addressing the specific needs of women, Treatment Improvement Protocol (TIP) Series, No. 51. HHS Publication No. (SMA) 13–4426. Rockville: Substance Abuse and Mental Health Services Administration; 2009.

    Google Scholar 

  7. Lindblad R, Hu L, Oden N, Wakim P, Rosa C, VanVeldhuisen P. Mortality rates among substance use disorder participants in clinical trials: pooled analysis of twenty-two clinical trials within the national drug abuse treatment clinical trials network. J Subst Abus Treat. 2016;70:73–80.

    Article  Google Scholar 

  8. Sofuoglu M, Dudish-Poulsen S, Nelson D, Pentel PR, Hatsukami DK. Sex and menstrual cycle differences in the subjective effects from smoked cocaine in humans. Exp Clin Psychopharmacol. 1999;7(3):274.

    Article  CAS  PubMed  Google Scholar 

  9. McCabe JE, Arndt S. Demographic and substance abuse trends among pregnant and non-pregnant women: eleven years of treatment admission data. Matern Child Health J. 2012;16(8):1696–702.

    Article  PubMed  Google Scholar 

  10. Garcia-Guix A, Mestre-Pinto JI, Tirado-Muñoz J, Domingo-Salvany A, Torrens M. Psychiatric co-morbidity among women with substance use disorders. Adv Dual Diagn. 2018;11(1):1–3.

    Article  Google Scholar 

  11. Frem Y, Torrens M, Domingo-Salvany A, Gilchrist G. Gender differences in lifetime psychiatric and substance use disorders among people who use substances in Barcelona. Spain Adv Dual Diagn. 2017;10(2):45–56.

    Article  Google Scholar 

  12. Krawczyk N, Feder KA, Saloner B, Crum RM, Kealhofer M, Mojtabai R. The association of psychiatric comorbidity with treatment completion among clients admitted to substance use treatment programs in a US national sample. Drug Alcohol Depend. 2017;175:157–63.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Eggleston AM, Calhoun PS, Svikis DS, Tuten M, Chisolm MS, Jones HE. Suicidality, aggression, and other treatment considerations among pregnant, substance-dependent women with posttraumatic stress disorder. Compr Psychiatry. 2009;50(5):415–23.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Melikian AA, Djordjevic MV, Hosey J, Zhang J, Chen S, Zang E, Muscat J, Stellman SD. Gender differences relative to smoking behavior and emissions of toxins from mainstream cigarette smoke. Nicotine Tob Res. 2007;9(3):377–87.

    Article  CAS  PubMed  Google Scholar 

  15. Perkins KA, Scott J. Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob Res. 2008;10(7):1245–50. https://doi.org/10.1080/14622200802097506.

    Article  CAS  PubMed  Google Scholar 

  16. Aguirre CG, Bello MS, Andrabi N, Pang RD, Hendricks PS, Bluthenthal RN, Leventhal AM. Gender, ethnicity, and their intersectionality in the prediction of smoking outcome expectancies in regular cigarette smokers. Behav Modif. 2016;40(1–2):281–302.

    Article  PubMed  Google Scholar 

  17. Smith PH, Bessette AJ, Weinberger AH, Sheffer CE, McKee SA. Sex/gender differences in smoking cessation: a review. Prev Med. 2016;92:135–40.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Smith PH, Weinberger AH, Zhang J, Emme E, Mazure CM, McKee SA. Sex differences in smoking cessation pharmacotherapy comparative efficacy: a network meta-analysis. Nicotine Tob Res. 2017;19(3):273–81.

    PubMed  Google Scholar 

  19. Pirie PL, Murray DM, Luepker RV. Gender differences in cigarette smoking and quitting in a cohort of young adults. Am J Public Health. 1991;81:324–7. [PubMed: 1994740]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Swan GE, Ward MM, Carmelli D, et al. Differential rates of relapse in subgroups of male and female smokers. J Clin Epidemiol. 1993;46:1041–53. [PubMed: 8263577]

    Article  CAS  PubMed  Google Scholar 

  21. Perkins KA, Levine M, Marcus M, Shiffman S, D'amico D, Miller A, Keins A, Ashcom J, Broge M. Tobacco withdrawal in women and menstrual cycle phase. J Consult Clin Psychol. 2000;68(1):176.

    Article  PubMed  Google Scholar 

  22. Franklin TR, Ehrman R, Lynch KG, Harper D, Sciortino N, O’Brien CP, Childress AR. Menstrual cycle phase at quit date predicts smoking status in an NRT treatment trial: a retrospective analysis. J Women's Health. 2008;17(2):287–92.

    Article  Google Scholar 

  23. Allen SS, Bade T, Center B, Finstad D, Hatsukami D. Menstrual phase effects on smoking relapse. Addiction. 2008;103(5):809–21.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Committee on Obstetric Practice. Committee opinion no. 721: smoking cessation during pregnancy. Obstet Gynecol. 2017;130(4):e200.

    Article  Google Scholar 

  25. Siu AL. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163(8):622–34.

    Article  PubMed  Google Scholar 

  26. Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018;5:CD000146.

    PubMed  Google Scholar 

  27. Tong VT, Dietz PM, Morrow B, et al. Trends in smoking before, during, and after pregnancy-pregnancy risk assessment monitoring system, United States, 40 sites, 2000–2010. MMWR Surveill Summ. 2013;62:1–19.

    PubMed  Google Scholar 

  28. National Institute on Alcohol Abuse and Alcoholism. Helping patients who drink too much: a clinician’s guide. 2005. NIH publication: 07-3769.

    Google Scholar 

  29. Kelly JF, Stout R, Zywiak W, Schneider R. A 3-year study of addiction mutual-help group participation following intensive outpatient treatment. Alcohol Clin Exp Res. 2006;30(8):1381–92.

    Article  PubMed  Google Scholar 

  30. American College of Obstetricians and Gynecologists, Committee on Health Care for Underserved Women. Committee opinion no. 496: at-risk drinking and alcohol dependence: obstetric and gynecologic implications. Obstet Gynecol. 2011;118(2 Pt 1):383.

    Google Scholar 

  31. Williams JF, Smith VC, Committee on Substance Abuse. Fetal alcohol spectrum disorders. Pediatrics. 2015;136:e1395. Oct 19:peds-2015.

    Article  PubMed  Google Scholar 

  32. Tan CH, Denny CH, Cheal NE, Sniezek JE, Kanny D. Alcohol use and binge drinking among women of childbearing age—United States, 2011–2013. MMWR Morb Mortal Wkly Rep. 2015;64(37):1042–6.

    Article  PubMed  Google Scholar 

  33. McLafferty LP, Becker M, Dresner N, Meltzer-Brody S, Gopalan P, Glance J, Victor GS, Mittal L, Marshalek P, Lander L, Worley LL. Guidelines for the management of pregnant women with substance use disorders. Psychosomatics. 2016;57(2):115–30.

    Article  PubMed  Google Scholar 

  34. May PA, Chambers CD, Kalberg WO, Zellner J, Feldman H, Buckley D, Kopald D, Hasken JM, Xu R, Honerkamp-Smith G, Taras H. Prevalence of fetal alcohol spectrum disorders in 4 US communities. JAMA. 2018;319(5):474–82.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Sokol RJ, Martier SS, Ager JW. The T-ACE questions: practical prenatal detection of risk-drinking. Am J Obstet Gynecol. 1989;160(4):863–70.

    Article  CAS  PubMed  Google Scholar 

  36. Chang G, Wilkins-Haug L, Berman S, Goetz MA. The TWEAK: application in a prenatal setting. J Stud Alcohol. 1999;60(3):306–9.

    Article  CAS  PubMed  Google Scholar 

  37. Bhat A, Hadley A. The management of alcohol withdrawal in pregnancy—case report, literature review and preliminary recommendations. Gen Hosp Psychiatry. 2015;37(3):273–e1.

    Article  PubMed  Google Scholar 

  38. Rolland B, Paille F, Gillet C, Rigaud A, Moirand R, Dano C, Dematteis M, Mann K, Aubin HJ. Pharmacotherapy for alcohol dependence: the 2015 recommendations of the French Alcohol Society, issued in partnership with the European Federation of Addiction Societies. CNS Neurosci Ther. 2016;22(1):25–37.

    Article  CAS  PubMed  Google Scholar 

  39. Giglia R, Binns C. Alcohol and lactation: a systematic review. Nutr Diet. 2006;63(2):103–16.

    Article  Google Scholar 

  40. Hasin DS, Kerridge BT, Saha TD, Huang B, Pickering R, Smith SM, Jung J, Zhang H, Grant BF. Prevalence and correlates of DSM-5 cannabis use disorder, 2012-2013: findings from the National Epidemiologic Survey on alcohol and related conditions–III. Am J Psychiatr. 2016;173(6):588–99.

    Article  PubMed  Google Scholar 

  41. Ryan-Ibarra S, Induni M, Ewing D. Prevalence of medical marijuana use in California, 2012. Drug Alcohol Rev. 2015;34(2):141–6.

    Article  PubMed  Google Scholar 

  42. Cooper ZD, Craft RM. Sex-dependent effects of cannabis and cannabinoids: a translational perspective. Neuropsychopharmacology. 2018;43(1):34.

    Article  CAS  PubMed  Google Scholar 

  43. Copeland J, Swift W, Rees V. Clinical profile of participants in a brief intervention program for cannabis use disorder. J Subst Abus Treat. 2001;20(1):45–52.

    Article  CAS  Google Scholar 

  44. Herrmann ES, Weerts EM, Vandrey R. Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users. Exp Clin Psychopharmacol. 2015;23(6):415.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Sherman BJ, McRae-Clark AL, Baker NL, Sonne SC, Killeen TK, Cloud K, Gray KM. Gender differences among treatment-seeking adults with cannabis use disorder: clinical profiles of women and men enrolled in the achieving cannabis cessation—evaluating N-acetylcysteine treatment (ACCENT) study. Am J Addict. 2017;26(2):136–44.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Metz TD, Stickrath EH. Marijuana use in pregnancy and lactation: a review of the evidence. Am J Obstet Gynecol. 2015;213(6):761–78.

    Article  PubMed  Google Scholar 

  47. Volkow ND, Compton WM, Wargo EM. The risks of marijuana use during pregnancy. JAMA. 2017;317(2):129–30.

    Article  PubMed  Google Scholar 

  48. Pearson G, Shiner M. Rethinking the generation gap: attitudes to illicit drugs among young people and adults. Crim Justice. 2002;2(1):71–86.

    Article  Google Scholar 

  49. Onaivi ES, Chaudhuri G, Abaci AS, Parker M, Manier DH, Martin PR, Hubbard JR. Expression of cannabinoid receptors and their gene transcripts in human blood cells. Prog Neuro-Psychopharmacol Biol Psychiatry. 1999;23(6):1063–77.

    Article  CAS  Google Scholar 

  50. Normandin MD, Zheng MQ, Lin KS, Mason NS, Lin SF, Ropchan J, Labaree D, Henry S, Williams WA, Carson RE, Neumeister A. Imaging the cannabinoid CB1 receptor in humans with [11C] OMAR: assessment of kinetic analysis methods, test–retest reproducibility, and gender differences. J Cereb Blood Flow Metab. 2015;35(8):1313–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Wiers CE, Shokri-Kojori E, Wong CT, Abi-Dargham A, Demiral ŞB, Tomasi D, Wang GJ, Volkow ND. Cannabis abusers show hypofrontality and blunted brain responses to a stimulant challenge in females but not in males. Neuropsychopharmacology. 2016;41(10):2596.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. El-Talatini MR, Taylor AH, Konje JC. The relationship between plasma levels of the endocannabinoid, anandamide, sex steroids, and gonadotrophins during the menstrual cycle. Fertil Steril. 2010;93(6):1989–96.

    Article  CAS  PubMed  Google Scholar 

  53. Sherman BJ, McRae-Clark AL. Treatment of cannabis use disorder: current science and future outlook. Pharmacother: J Hum Pharmacol Drug Ther. 2016;36(5):511–35.

    Article  Google Scholar 

  54. Ko JY, Farr SL, Tong VT, Creanga AA, Callaghan WM. Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age. Am J Obstet Gynecol. 2015;213(2):201–e1.

    Article  PubMed  Google Scholar 

  55. Brown QL, Sarvet AL, Shmulewitz D, Martins SS, Wall MM, Hasin DS. Trends in marijuana use among pregnant and nonpregnant reproductive-aged women, 2002–2014. JAMA. 2017;317(2):207–9.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Fantasia HC. Pharmacologic implications of marijuana use during pregnancy. Nurs Womens Health. 2017;21(3):217–23.

    Article  PubMed  Google Scholar 

  57. Varner MW, Silver RM, Hogue CJ, Willinger M, Parker CB, Thorsten VR, Goldenberg RL, Saade GR, Dudley DJ, Coustan D, Stoll B. Association between stillbirth and illicit drug use and smoking during pregnancy. Obstet Gynecol. 2014;123(1):113.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. El Marroun H, Tiemeier H, Steegers EA, Jaddoe VW, Hofman A, Verhulst FC, Van Den Brink W, Huizink AC. Intrauterine cannabis exposure affects fetal growth trajectories: the Generation R Study. J Am Acad Child Adolesc Psychiatry. 2009;48(12):1173–81.

    Article  PubMed  Google Scholar 

  59. Gunn JK, Rosales CB, Center KE, Nuñez A, Gibson SJ, Christ C, Ehiri JE. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open. 2016;6(4):e009986.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Fried PA, Makin JE. Neonatal behavioural correlates of prenatal exposure to marihuana, cigarettes and alcohol in a low risk population. Neurotoxicol Teratol. 1987;9(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  61. de Moraes Barros MC, Guinsburg R, de Araújo Peres C, Mitsuhiro S, Chalem E, Laranjeira RR. Exposure to marijuana during pregnancy alters neurobehavior in the early neonatal period. J Pediatr. 2006;149(6):781–7.

    Article  CAS  PubMed  Google Scholar 

  62. Richardson GA, Ryan C, Willford J, Day NL, Goldschmidt L. Prenatal alcohol and marijuana exposure: effects on neuropsychological outcomes at 10 years. Neurotoxicol Teratol. 2002;24(3):309–20.

    Article  CAS  PubMed  Google Scholar 

  63. Klonoff-Cohen H, Lam-Kruglick P. Maternal and paternal recreational drug use and sudden infant death syndrome. Arch Pediatr Adolesc Med. 2001;155(7):765–70.

    Article  CAS  PubMed  Google Scholar 

  64. Astley SJ, Little RE. Maternal marijuana use during lactation and infant development at one year. Neurotoxicol Teratol. 1990;12(2):161–8.

    Article  CAS  PubMed  Google Scholar 

  65. Perez-Reyes M, Wall ME. Presence of delta-9-tetrahydrocannabinol in human milk. N Engl J Med. 1982;307:819–20.

    Article  CAS  PubMed  Google Scholar 

  66. American College of Obstetricians and Gynecologists. Marijuana use during pregnancy and lactation. Committee opinion no. 722. Obstet Gynecol. 2017;130(4):e205–9.

    Article  Google Scholar 

Opioid References

  1. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. Multiple Cause of Death, 1999–2016 on CDC WONDER Online Database, released 2017. Data are from the Multiple Cause of Death Files, 1999–2016, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. https://wonder.cdc.gov/mcd-icd10.html. Published 2017. Accessed 8 Aug 2018.

  2. Jones CM, Logan J, Gladden RM, Bohm MK. Vital signs: demographic and substance use trends among heroin users—United States, 2002–2013. MMWR. Morb Mortal Wkly Rep. 2015;64(26):719.

    Google Scholar 

  3. Han B, Compton WM, Jones CM, Cai R. Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003–2013. JAMA. 2015;314(14):1468–78.

    Article  CAS  PubMed  Google Scholar 

  4. Cicero TJ, Kasper Z, Ellis MS. Increased use of heroin as an initiating opioid of abuse: further considerations and policy implications. Addict Behav. 2018;87:267–71.

    Article  PubMed  Google Scholar 

  5. Ailes EC, Dawson AL, Lind JN, Gilboa SM, Frey MT, Broussard CS, Honein MA. Opioid prescription claims among women of reproductive age – United States, 2008–2012. MMWR Morb Mortal Wkly Rep. 2015;64(2):37–41.

    PubMed  PubMed Central  Google Scholar 

  6. Riley IIIJL, Robinson ME, Wise EA, Myers CD, Fillingim RB. Sex differences in the perception of noxious experimental stimuli: a meta-analysis. Pain. 1998;74(2–3):181–7.

    Article  PubMed  Google Scholar 

  7. Gerdle B, Björk J, Cöster L, Henriksson KG, Henriksson C, Bengtsson A. Prevalence of widespread pain and associations with work status: a population study. BMC Musculoskelet Disord. 2008;9(1):102.

    Article  PubMed  PubMed Central  Google Scholar 

  8. McHugh RK, DeVito EE, Dodd D, Carroll KM, Potter JS, Greenfield SF, Connery HS, Weiss RD. Gender differences in a clinical trial for prescription opioid dependence. J Subst Abus Treat. 2013;45(1):38–43.

    Article  Google Scholar 

  9. Powis B, Griffiths P, Gossop M, Strang J. The differences between male and female drug users: community samples of heroin and cocaine users compared. Subst Use Misuse. 1996;31(5):529–43.

    Article  CAS  PubMed  Google Scholar 

  10. Bryant J, Brener L, Hull P, Treloar C. Needle sharing in regular sexual relationships: an examination of serodiscordance, drug using practices, and the gendered character of injecting. Drug Alcohol Depend. 2010;107(2–3):182–7.

    Article  PubMed  Google Scholar 

  11. Lum PJ, Sears C, Guydish J. Injection risk behavior among women syringe exchangers in San Francisco. Subst Use Misuse. 2005;40(11):1681–96.

    Article  PubMed  Google Scholar 

  12. Dwyer R, Richardson D, Ross MW, Wodak A, Miller ME, Gold J. A comparison of HIV risk between women and men who inject drugs. AIDS Educ Prev Off Publ Int Soc AIDS Educ. 1994;6(5):379–89.

    CAS  Google Scholar 

  13. Back SE, Lawson KM, Singleton LM, Brady KT. Characteristics and correlates of men and women with prescription opioid dependence. Addict Behav. 2011;36(8):829–34.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Gros DF, Milanak ME, Brady KT, Back SE. Frequency and severity of comorbid mood and anxiety disorders in prescription opioid dependence. Am J Addict. 2013;22(3):261–5.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Jones HE, Fitzgerald H, Johnson RE, Jones HE, Fitzgerald H, Johnson RE. Males and females differ in response to opioid agonist medications. Am J Addict. 2005;14(3):223–33.

    Article  PubMed  Google Scholar 

  16. Schottenfeld RS, Pakes JR, Kosten TR. Prognostic factors in buprenorphine-versus methadone-maintained patients. J Nerv Ment Dis. 1998;186(1):35–43.

    Article  CAS  PubMed  Google Scholar 

  17. Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, Meyer CR, Koeppe RA, Stohler CS. μ-Opioid receptor-mediated antinociceptive responses differ in men and women. J Neurosci. 2002;22(12):5100–7.

    Article  CAS  PubMed  Google Scholar 

  18. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD. Kappa–opioids produce significantly greater analgesia in women than in men. Nat Med. 1996;2(11):1248.

    Article  CAS  PubMed  Google Scholar 

  19. Kreek MJ, Schluger J, Borg L, Gunduz M, Ho A. Dynorphin A1–13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. J Pharmacol Exp Ther. 1999;288(1):260–9.

    CAS  PubMed  Google Scholar 

  20. Unger A, Jung E, Winklbaur B, Fischer G. Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine. J Addict Dis. 2010;29(2):217–30.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Karuntzos GT, Caddell JM, Dennis ML. Gender differences in vocational needs and outcomes for methadone treatment clients. J Psychoactive Drugs. 1994;26(2):173–80.

    Article  CAS  PubMed  Google Scholar 

  22. Zhang Z, Friedmann PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. Addiction. 2003;98(5):673–84.

    Article  PubMed  Google Scholar 

  23. Bateman BT, Hernandez-Diaz S, Rathmell JP, Seeger JD, Doherty M, Fischer MA, Huybrechts KF. Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States. Anesthesiol: J Am Soc Anesthesiologists. 2014;120(5):1216–24.

    Article  Google Scholar 

  24. Desai RJ, Hernandez-Diaz S, Bateman BT, Huybrechts KF. Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstet Gynecol. 2014;123(5):997.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. JAMA. 2012;307(18):1934–40.

    Article  CAS  PubMed  Google Scholar 

  26. Epstein RA, Bobo WV, Martin PR, Morrow JA, Wang W, Chandrasekhar R, Cooper WO. Increasing pregnancy-related use of prescribed opioid analgesics. Ann Epidemiol. 2013;23(8):498–503.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Maeda A, Bateman BT, Clancy CR, Creanga AA, Leffert LR. Opioid abuse and dependence during pregnancy temporal trends and obstetrical outcomes. J Am Soc Anesthesiologists. 2014;121(6):1158–65.

    Google Scholar 

  28. Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol. 2015;35(8):650.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. ACOG Committee on Health Care for Underserved Women. ACOG committee opinion no. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol. 2012;119(5):1070.

    Article  Google Scholar 

  30. Luty J, Nikolaou V. Bearn J. Is opiate detoxification unsafe in pregnancy? J Subst Abus Treat. 2003;24(4):363–7.

    Article  Google Scholar 

  31. Blinick G, Wallach RC, Jerez E, Ackerman BD. Drug addiction in pregnancy and the neonate. Am J Obstetr Gynecol. 1976;125(2):135–42.

    Article  CAS  Google Scholar 

  32. Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel GD Jr. Opioid detoxification in pregnancy. Obstet Gynecol. 1998;92(5):854–8.

    CAS  PubMed  Google Scholar 

  33. Jones HE, O’grady KE, Malfi D, Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict. 2008;17(5):372–86.

    Article  PubMed  Google Scholar 

  34. Maas U, Kattner E, Weingart-Jesse B, Schäfer A, Obladen M. Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy. J Perinat Med-Off J WAPM. 1990;18(2):111–8.

    Article  CAS  Google Scholar 

  35. McCarthy JJ, Leamon MH, Parr MS, Anania B. High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Am J Obstet Gynecol. 2005;193(3):606–10.

    Article  CAS  PubMed  Google Scholar 

  36. Haas AL, Peters RH. Development of substance abuse problems among drug-involved offenders: evidence for the telescoping effect. J Subst Abus. 2000;12(3):241–53.

    Article  CAS  Google Scholar 

  37. White KA, Brady KT, Sonne S. Gender differences in patterns of cocaine use. Am J Addict. 1996;5(3):259–61.

    Article  Google Scholar 

  38. Brecht ML, O'Brien A, Von Mayrhauser C, Anglin MD. Methamphetamine use behaviors and gender differences. Addict Behav. 2004;29(1):89–106.

    Article  PubMed  Google Scholar 

  39. Durell TM, Kroutil LA, Crits-Christoph P, Barchha N, Van Brunt DL. Prevalence of nonmedical methamphetamine use in the United States. Subst Abuse Treat Prev Policy. 2008;3(1):19.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The TEDS report: gender differences in primary substance of abuse across age groups. 2014. Rockville.

    Google Scholar 

  41. Hser YI, Evans E, Huang YC. Treatment outcomes among women and men methamphetamine abusers in California. J Subst Abus Treat. 2005;28(1):77–85.

    Article  Google Scholar 

  42. Rawson RA, Gonzales R, Obert JL, McCann MJ, Brethen P. Methamphetamine use among treatment-seeking adolescents in Southern California: participant characteristics and treatment response. J Subst Abus Treat. 2005;29(2):67–74.

    Article  Google Scholar 

  43. Kim JY, Fendrich M. Gender differences in juvenile arrestees’ drug use, self-reported dependence, and perceived need for treatment. Psychiatr Serv. 2002;53(1):70–5.

    Article  PubMed  Google Scholar 

  44. Dluzen DE, Liu B. Gender differences in methamphetamine use and responses: a review. Gend Med. 2008;5(1):24–35.

    Article  PubMed  Google Scholar 

  45. Cretzmeyer M, Sarrazin MV, Huber DL, Block RI, Hall JA. Treatment of methamphetamine abuse: research findings and clinical directions. J Subst Abus Treat. 2003;24(3):267–77.

    Article  Google Scholar 

  46. Sofuoglu M, Mitchell E, Kosten TR. Effects of progesterone treatment on cocaine responses in male and female cocaine users. Pharmacol Biochem Behav. 2004;78(4):699–705.

    Article  CAS  PubMed  Google Scholar 

  47. Evans SM, Foltin RW. Exogenous progesterone attenuates the subjective effects of smoked cocaine in women, but not in men. Neuropsychopharmacology. 2006;31(3):659.

    Article  CAS  PubMed  Google Scholar 

  48. Justice AJ, de Wit H. Acute effects of d-amphetamine during the follicular and luteal phases of the menstrual cycle in women. Psychopharmacology. 1999;145(1):67–75.

    Article  CAS  PubMed  Google Scholar 

  49. Justice AJ, De Wit H. Acute effects of d-amphetamine during the early and late follicular phases of the menstrual cycle in women. Pharmacol Biochem Behav. 2000;66(3):509–15.

    Article  CAS  PubMed  Google Scholar 

  50. Agabio R, Campesi I, Pisanu C, Gessa GL, Franconi F. Sex differences in substance use disorders: focus on side effects. Addict Biol. 2016;21(5):1030–42.

    Article  CAS  PubMed  Google Scholar 

  51. Adinoff B, Williams MJ, Best SE, Harris TS, Chandler P, Devous MD Sr. Sex differences in medial and lateral orbitofrontal cortex hypoperfusion in cocaine-dependent men and women. Gend Med. 2006;3(3):206–22.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Shetty V, Harrell L, Murphy DA, Vitero S, Gutierrez A, Belin TR, Dye BA, Spolsky VW. Dental disease patterns in methamphetamine users: Findings in a large urban sample. J Am Dent Assoc. 2015;146(12):875–85.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Kittirattanapaiboon P, Srikosai S, Wittayanookulluk A. Methamphetamine use and dependence in vulnerable female populations. Curr Opin Psychiatry. 2017;30(4):247–52.

    Article  PubMed  Google Scholar 

  54. Dahlman D, Håkansson A, Björkman P, Blomé MA, Kral AH. Correlates of skin and soft tissue infections in injection drug users in a syringe-exchange program in Malmö, Sweden. Subst Use Misuse. 2015;50(12):1529–35.

    Article  PubMed  Google Scholar 

  55. Hughes PH, Coletti SD, Neri RL, Urmann CF, Stahl S, Sicilian DM, Anthony JC. Retaining cocaine-abusing women in a therapeutic community: the effect of a child live-in program. Am J Public Health. 1995;85(8_Pt_1):1149–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Schottenfeld RS, Moore B, Pantalon MV. Contingency management with community reinforcement approach or twelve-step facilitation drug counseling for cocaine dependent pregnant women or women with young children. Drug Alcohol Depend. 2011;118(1):48–55.

    Article  PubMed  Google Scholar 

  57. Bhuvaneswar CG, Chang G, Epstein LA, Stern TA. Cocaine and opioid use during pregnancy: prevalence and management. Prim Care Companion J Clin Psychiatry. 2008;10(1):59.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Wendell AD. Overview and epidemiology of substance abuse in pregnancy. Clin Obstet Gynecol. 2013;56(1):91–6.

    Article  PubMed  Google Scholar 

  59. Ostrea EM, Brady M, Gause S, Raymundo AL, Stevens M. Drug screening of newborns by meconium analysis: a large-scale, prospective, epidemiologic study. Pediatrics. 1992;89(1):107–13.

    PubMed  Google Scholar 

  60. Fallone MD, LaGasse LL, Lester BM, Shankaran S, Bada HS, Bauer CR. Reactivity and regulation of motor responses in cocaine-exposed infants. Neurotoxicol Teratol. 2014;43:25–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Zuckerman B, Frank DA, Mayes L. Cocaine-exposed infants and developmental outcomes: crack kids revisited. JAMA. 2002;287(15):1990–1.

    Article  PubMed  Google Scholar 

  62. Frank DA, Augustyn M, Knight WG, Pell T, Zuckerman B. Growth, development, and behavior in early childhood following prenatal cocaine exposure: a systematic review. JAMA. 2001;285(12):1613–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Chaplin TM, Freiburger MB, Mayes LC, Sinha R. Prenatal cocaine exposure, gender, and adolescent stress response: a prospective longitudinal study. Neurotoxicol Teratol. 2010;32(6):595–604.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Bandstra ES, Vogel AL, Morrow CE, Xue L, Anthony JC. Severity of prenatal cocaine exposure and child language functioning through age seven years: a longitudinal latent growth curve analysis. Subst Use Misuse. 2004;39(1):25–59.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Singer LT, Arendt R, Minnes S, Farkas K, Salvator A, Kirchner HL, Kliegman R. Cognitive and motor outcomes of cocaine-exposed infants. JAMA. 2002;287(15):1952–60.

    Article  CAS  PubMed  Google Scholar 

  66. Mansoor E, Morrow CE, Accornero VH, Xue L, Johnson AL, Anthony JC, Bandstra ES. Longitudinal effects of prenatal cocaine use on mother-child interactions at ages 3 and 5. J Dev Behav Pediatr: JDBP. 2012;33(1):32.

    Article  PubMed  Google Scholar 

  67. Strathearn L, Mayes LC. Cocaine addiction in mothers. Ann N Y Acad Sci. 2010;1187(1):172–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, USA

    Whitney Peters

  2. Medical University of South Carolina, Institute of Psychiatry, Charleston, SC, USA

    Connie Guille

  3. Department of Psychiatry, Brigham and Women’s Hospital, Boston, MA, USA

    Leena Mittal

Authors
  1. Whitney Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Connie Guille
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leena Mittal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leena Mittal .

Editor information

Editors and Affiliations

  1. Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA

    Mary Angela O’Neal

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Peters, W., Guille, C., Mittal, L. (2019). Substance Use Disorders in Women. In: O’Neal, M. (eds) Neurology and Psychiatry of Women. Springer, Cham. https://doi.org/10.1007/978-3-030-04245-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-04245-5_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-04244-8

  • Online ISBN: 978-3-030-04245-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation